Legumain-induced intracerebrally crosslinked vesicles for suppressing efflux transport of Alzheimer's disease multi-drug nanosystem

Legumain-induced intracerebrally crosslinked vesicles for suppressing efflux transport of Alzheimer's disease multi-drug nanosystem

Brain barrier is both a protective permeability hurdle and a limitation site where therapeutic agents are excluded to enter the target region. Designing drug vehicle to overcome this notorious barrier bottle is challenging. Herein, we construct a stimuli-responsive self-assembled nanovesicle that de...

Full description

Bibliographic Details
Main Authors:	Fuxin Jiang, Jian Ren, Yachai Gao, Jinna Wang, Yiping Zhao, Fengying Dai
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2021-06-01
Series:	Bioactive Materials
Subjects:	Legumain Brain barrier Efflux transport Multi-drug delivery Alzheimer's disease
Online Access:	http://www.sciencedirect.com/science/article/pii/S2452199X2030311X

Similar Items

The Asparaginyl Endopeptidase Legumain: An Emerging Therapeutic Target and Potential Biomarker for Alzheimer’s Disease
by: Mingke Song
Published: (2022-09-01)

Characterization of Legumain Degradome Confirms Narrow Cleavage Specificity
by: Robert Vidmar, et al.
Published: (2019-02-01)

Screening and Identification of Microbial Derivatives for Inhibiting Legumain: An In silico Approach
by: Bandi Deepa Reddy, et al.
Published: (2018-09-01)

Prospective study on relationship between legumain and early neurological deterioration in patients with acute large artery atherosclerotic stroke
by: RONG Tianyi, HUA Yun, CHEN Deyan, HE Min
Published: (2021-04-01)

The legumain McPAL1 from Momordica cochinchinensis is a highly stable Asx-specific splicing enzyme
by: Liew, Heng Tai, et al.
Published: (2022)

Legumain in Acute Coronary Syndromes: A Substudy of the PLATO (Platelet Inhibition and Patient Outcomes) Trial
by: Ida Gregersen, et al.
Published: (2020-09-01)

The High Expression of Legumain in Canine Neoplasms: A Retrospective Analysis of 100 Cases
by: Chiao-Hsu Ke, et al.
Published: (2022-02-01)

Protease activity of legumain is inhibited by an increase of cystatin E/M in the DJ-1-knockout mouse spleen, cerebrum and heart
by: Takuya Yamane, et al.
Published: (2017-03-01)

The Cysteine Protease Legumain Is Upregulated by Vitamin D and Is a Regulator of Vitamin D Metabolism in Mice
by: Karl Martin Forbord, et al.
Published: (2023-12-01)

Active legumain promotes invasion and migration of neuroblastoma by regulating epithelial-mesenchymal transition
by: Zhang Min, et al.
Published: (2022-06-01)

Identification of the Cysteine Protease Legumain as a Potential Chronic Hypoxia-Specific Multiple Myeloma Target Gene
by: Ada-Sophia Clees, et al.
Published: (2022-01-01)

Asparaginyl Endopeptidase (Legumain) Supports Human Th1 Induction via Cathepsin L-Mediated Intracellular C3 Activation
by: Simon Freeley, et al.
Published: (2018-10-01)

Aronia juice improves working memory and suppresses δ-secretase activity in 5XFAD mice
by: Takuya Yamane, et al.
Published: (2023-08-01)

The Mammalian Cysteine Protease Legumain in Health and Disease
by: Rigmor Solberg, et al.
Published: (2022-12-01)

Legumain/pH dual-responsive lytic peptide–paclitaxel conjugate for synergistic cancer therapy
by: Shanshan Zheng, et al.
Published: (2022-12-01)

Ultrasound-mediated blood–brain barrier opening uncovers an intracerebral perivenous fluid network in persons with Alzheimer’s disease
by: Rashi I. Mehta, et al.
Published: (2023-06-01)

Development of a Promising <sup>18</sup>F-Radiotracer for PET Imaging Legumain Activity In Vivo
by: Chunmei Lu, et al.
Published: (2022-04-01)

UHPLC-MS/MS Assay for Quantification of Legubicin, a Novel Doxorubicin-Based Legumain-Activated Prodrug, and Its Application to Pharmacokinetic and Tissue Distribution Studies
by: Liyuan Ma, et al.
Published: (2024-02-01)

Roles of Species-Specific Legumains in Pathogenicity of the Pinewood Nematode <i>Bursaphelenchus xylophilus</i>
by: Xi Zhang, et al.
Published: (2022-09-01)

Substrate-binding glycine residues are major determinants for hydrolase and ligase activity of plant legumains
by: Hemu, Xinya, et al.
Published: (2023)

Associations of Interleukin 10, Matrix Metallopeptidase 9, and Legumain with Blood Pressure Variability and Neurologic Outcomes in Patients with Ischemic Stroke
by: Rong T, et al.
Published: (2020-12-01)

A Novel Legumain-Like Protease in Macrobrachium nipponense: Identification, Characterization, and Function Analysis in Ovary Maturation
by: Sufei Jiang, et al.
Published: (2022-03-01)

Legumain Regulates Differentiation Fate of Human Bone Marrow Stromal Cells and Is Altered in Postmenopausal Osteoporosis
by: Abbas Jafari, et al.
Published: (2017-02-01)

Imaging asparaginyl endopeptidase (AEP) in the live brain as a biomarker for Alzheimer’s disease
by: Shan-Shan Wang, et al.
Published: (2021-08-01)

Age-Related Functional and Expressional Changes in Efflux Pathways at the Blood-Brain Barrier
by: Franciska Erdő, et al.
Published: (2019-07-01)

<i>Trichomonas vaginalis</i> Legumain-2, TvLEGU-2, Is an Immunogenic Cysteine Peptidase Expressed during Trichomonal Infection
by: Esly Alejandra Euceda-Padilla, et al.
Published: (2024-01-01)

ABCA1‐Mediated Cholesterol Efflux Capacity to Cerebrospinal Fluid Is Reduced in Patients With Mild Cognitive Impairment and Alzheimer's Disease
by: Hussein N. Yassine, et al.
Published: (2016-02-01)

Cystatin M/E (Cystatin 6): A Janus-Faced Cysteine Protease Inhibitor with Both Tumor-Suppressing and Tumor-Promoting Functions
by: Gilles Lalmanach, et al.
Published: (2021-04-01)

Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model
by: Ju Wang, et al.
Published: (2021-03-01)

Multidrug Efflux Pumps in Bacteria and Efflux Pump Inhibitors
by: Sreekantan Abhirami P., et al.
Published: (2022-10-01)

Efflux pumps as potential targets for biofilm inhibition
by: Jingyi Ren, et al.
Published: (2024-02-01)

Lipid efflux in human and mouse macrophagic cells: evidence for differential regulation of phospholipid and cholesterol efflux
by: Robert S. Kiss, et al.
Published: (2005-09-01)

Multidrug Efflux Systems in Microaerobic and Anaerobic Bacteria
by: Zeling Xu, et al.
Published: (2015-08-01)

Consideration of Metabolite Efflux in Radiolabelled Choline Kinetics
by: Yunqing Li, et al.
Published: (2021-08-01)

Clinical Status of Efflux Resistance Mechanisms in Gram-Negative Bacteria
by: Anne Davin-Regli, et al.
Published: (2021-09-01)

Role of efflux pumps, their inhibitors, and regulators in colistin resistance
by: Yinhuan Ding, et al.
Published: (2023-08-01)

Multidrug Efflux Systems in Helicobacter cinaedi
by: Yoshiaki Kawamura, et al.
Published: (2012-11-01)

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems
by: Yang Han, et al.
Published: (2020-01-01)

Is the efflux pump inhibitor Verapamil a potential booster for isoniazid against Mycobacterium tuberculosis?
by: Renata Claro Ribeiro do Amaral, et al.
Published: (2020-11-01)

The Contribution of Efflux Systems to Levofloxacin Resistance in <i>Stenotrophomonas maltophilia</i> Clinical Strains Isolated in Warsaw, Poland
by: Olga M. Zając, et al.
Published: (2022-07-01)